Polls

Which insulin pump do you prefer for most of your patients? Medtronic, Tandem, or Omnipod? Follow the link to share your opinion.

Have you provided all your new patients who take insulin with a prescription for Glucagon or similar product? Follow the link to see how you and your colleagues compare.

Should we treat prediabetes pharmaceutically, along with diet and physical activity, for patients with an A1c of 6-6.4%? Follow the link to see how you compare to your colleagues.

With all the new insulin pump technology, do you feel that more patients, with either type 1 or type 2 using insulin, will move towards the smart pump rather than an insulin pump? Follow the link to see how you compare to your colleagues.

Do you consider ethnicity when determining the best treatment options for your patients? Follow the link to see how you and your colleagues compare.

Diabetes in Control readers are being asked to participate in exclusive research that will provide new insights into what you think about insulin pumps and daily injections. Whether you’re a patient, a patient family member, medical professional or diabetes educator, we need to hear from you. Please take a few moments to take our survey and help our research. The survey takes only about 3 minutes, is completely anonymous, and lets you make your voice heard in analysis that can potentially influence the future of insulin delivery research and development.

When pricing for CGM systems comes down to less than using a blood glucose monitor with strips, will you recommend these to your patients who do not take insulin?

- Yes
- No
- For my patients who are motivated
- For my patients who are not motivated

Follow the link to see how you and your colleagues compare.

Do you provide pharmaceutical treatment for your patients who have prediabetes besides motivating them to change lifestyles? Follow the link to share your experience.

If you could have any A1c result for yourself what would that be?

- Below 8%
- Below 7%
- Below 6%
- Below 5%

Follow the link to see how you and your colleagues compare.

What is your top concern when prescribing SGLT-2 inhibitors to patients with diabetes?

- Amputation risk
- Infection risk
- Kidney risk
- Price

Follow the link and see how you compare to your colleagues.